April 2022: Drug Pipeline Updates
The table provided is a review of notable updates that occurred in April 2022 for investigational products in development.
The table provided is a review of notable updates that occurred in April 2022 for investigational products in development.
Laboratory analyses revealed certain Artri and Ortiga products contain undeclared drug ingredients.
The phase 3 ATOM study evaluated the efficacy and safety of abaloparatide in 228 men with osteoporosis.
The update is based on data from an open-label, single-arm histomorphometry study.
The network meta-analysis compared the effects of 9 osteoporosis drugs on BMD.
Risk factor assessment can identify candidates for screening; nonpharmacologic measures appropriate for all postmenopausal women
Oral bisphosphonates should be continued without delay; one-week interval recommended between IV bisphosphonate and vaccine
Patterns of drug prescribing for the treatment of osteoporosis often do not follow clinical practice guidelines
To determine the association between cumulative exposure of potent and very potent TCSs and osteoporosis and MOF risk, study authors utilized the Danish nationwide registries.
Oral, inhaled corticosteroid use linked to increased risk for osteoporosis, fragility fractures